Alan H. Auerbach Sells 33,841 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) Stock

Puma Biotechnology, Inc. (NASDAQ:PBYI) CEO Alan H. Auerbach sold 33,841 shares of the business’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $3.15, for a total transaction of $106,599.15. Following the sale, the chief executive officer now directly owns 7,029,674 shares of the company’s stock, valued at $22,143,473.10. This represents a 0.48 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Puma Biotechnology Stock Performance

PBYI stock opened at $2.95 on Friday. Puma Biotechnology, Inc. has a 1-year low of $2.22 and a 1-year high of $7.73. The business has a 50-day moving average price of $2.99 and a 200 day moving average price of $2.97. The company has a market capitalization of $144.81 million, a P/E ratio of 6.15 and a beta of 1.10. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.42 and a quick ratio of 1.40.

Puma Biotechnology (NASDAQ:PBYI) last posted its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported $0.41 EPS for the quarter, beating the consensus estimate of $0.31 by $0.10. Puma Biotechnology had a net margin of 9.56% and a return on equity of 41.60%. The business had revenue of $80.50 million during the quarter, compared to analyst estimates of $71.32 million. During the same quarter in the previous year, the business posted $0.12 EPS. As a group, equities research analysts forecast that Puma Biotechnology, Inc. will post 0.31 EPS for the current fiscal year.

Institutional Trading of Puma Biotechnology

A number of hedge funds have recently bought and sold shares of the stock. SG Americas Securities LLC purchased a new position in shares of Puma Biotechnology in the 3rd quarter valued at $34,000. Franklin Resources Inc. bought a new stake in Puma Biotechnology during the third quarter valued at about $41,000. Dynamic Technology Lab Private Ltd purchased a new position in Puma Biotechnology in the third quarter valued at about $44,000. Patriot Financial Group Insurance Agency LLC raised its holdings in Puma Biotechnology by 72.7% in the third quarter. Patriot Financial Group Insurance Agency LLC now owns 19,000 shares of the biopharmaceutical company’s stock worth $48,000 after purchasing an additional 8,000 shares in the last quarter. Finally, Royce & Associates LP lifted its position in shares of Puma Biotechnology by 71.8% during the third quarter. Royce & Associates LP now owns 20,165 shares of the biopharmaceutical company’s stock valued at $51,000 after buying an additional 8,427 shares during the last quarter. Hedge funds and other institutional investors own 61.29% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have commented on PBYI. StockNews.com downgraded shares of Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research note on Friday, December 6th. HC Wainwright reissued a “buy” rating and issued a $7.00 price objective on shares of Puma Biotechnology in a research note on Monday, December 23rd.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.